Vasavaleha
Polyherbal Formulation
Vasavaleha is a classical Ayurvedic polyherbal semi-solid formulation, primarily featuring Vasaka (Justicia adhatoda). It's traditionally regarded for its claimed benefits in respiratory and inflammatory conditions, aiming to balance Kapha and Pitta doshas. This complex mixture is prevalent in Ayurvedic practices for its historical use in supporting overall well-being.
PLANT FAMILY
Several Families
AYURVEDIC ACTION
Kapha ↓, Pitta ↓
ACTIVE COMPOUNDS
Polyherbal (complex mixture)
What is Vasavaleha?
Vasavaleha is a classical Ayurvedic polyherbal formulation, specifically a semi-solid preparation (leha) used in traditional Indian medicine. It is primarily composed of Vasaka (Justicia adhatoda), a prominent herb known for its benefits, along with other synergistic herbs and natural sweeteners.
This traditional medicine is typically processed into a jam-like consistency and is highly regarded in Ayurvedic practices, particularly for respiratory and inflammatory conditions due to the properties of its herbal constituents. It is a complex mixture rather than a single plant.
Other Names of Vasavaleha
- Vasa Avaleha
- Vasaka Avaleha
Heading
<h3> Absolute Contraindications of Vasavaleha </h3> <h4> Pregnancy (risk of uterine stimulation / abortion) [In layman terms]</h4> <ul> <li> 🤰 <li> Recommendation: Do not take Vasavaleha during pregnancy; if pregnant and exposed, stop it and speak to your doctor or obstetrician immediately. <li> Reasoning: Adhatoda (Vasa) contains alkaloids that in animal studies have shown uterine-stimulating and abortifacient effects; caution is based on these reproductive-toxicity signals from preclinical data. <li> Scientific_Study_Title: Commonly used Indian abortifacient plants with special reference to their teratologic effects in rats. <li> Scientific_Study_Authors: Sharma N., et al. <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/1608272/ <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: In an experimental series the authors screened several traditionally used Indian plants for effects on pregnancy in rats. Leaf extracts of Adhatoda vasica produced complete abortifacient outcomes at the tested dose (equivalent to 175 mg/kg of starting dry material) in the animal model. The report documents anti-implantation and abortive actions in treated animals and highlights that traditional usage as an abortifacient has experimental support in rodents. The authors conclude that A. vasica extracts show strong teratologic potential under the study conditions and should be used cautiously in reproductive-age women.</p> </li> </ul> <h4>Concurrent use with critical CYP3A4-metabolized drugs (e.g., some statins, certain anticancer/antiretroviral drugs) [In layman terms]</h4> <ul> <li> ⚠️ <li> Recommendation: Avoid taking Vasavaleha together with important drugs that are primarily broken down by CYP3A4 unless a clinician supervises and monitors drug levels/effects. <li> Reasoning: Guggul (a common Vasavaleha ingredient) contains guggulsterones that can activate the pregnane X receptor and increase CYP3A gene expression; that may change blood levels of many prescription medicines. <li> Scientific_Study_Title: Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. <li> Scientific_Study_Authors: Brobst DE, Ding X, Creech KL, Goodwin B, Kelley B, Staudinger JL. <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/15075359/ <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: Laboratory work showed that guggulsterones (active compounds from Commiphora) bind and activate the pregnane X receptor (PXR) and, through this mechanism, increase expression of CYP3A enzymes in rodent and human hepatocytes. Induction of CYP3A is a well-recognized mechanism that accelerates metabolism of many drugs. The authors warn that gymnastic changes in enzyme expression caused by guggulsterones could lead to clinically important herb-drug interactions and recommend cautious use of guggul-containing products when people take medications metabolized by CYP3A family enzymes.</p> </li> </ul> <h4>Concurrent use with anticoagulants (e.g., warfarin) [In layman terms]</h4> <ul> <li> 🩸 <li> Recommendation: Do not combine Vasavaleha with warfarin or similar blood thinners without urgent medical supervision and INR monitoring; consider avoiding the herbal product while on anticoagulation. <li> Reasoning: Case reports and pharmacologic data show Commiphora species and multi-herbal products can alter anticoagulant effect (either increasing or decreasing warfarin activity) likely via metabolic interactions or complex herb effects on clotting. <li> Scientific_Study_Title: Antagonism of the anticoagulant effect of warfarin caused by the use of Commiphora molmol as a herbal medication: a case report. <li> Scientific_Study_Authors: (case report authors as indexed on PubMed) <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/15814041/ <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: The published case described a patient stabilized on warfarin who experienced loss of anticoagulant effect after starting a Commiphora herbal product; the authors concluded the herb likely antagonized warfarin’s effect. While the report describes a different Commiphora species, it illustrates that oleo-gum resins from this botanical group (including guggul) can alter warfarin activity. Clinically, such interactions produced dangerous reductions in INR and are cited as a reason to avoid combining warfarin with similar herbal resins without close monitoring.</p> </li> </ul> <h3> Relative Contraindications of Vasavaleha </h3> <h4>Children (safety not established in very young children) [In layman terms]</h4> <ul> <li> 👶 <li> Recommendation: Use only under pediatrician/vaidyacare guidance; avoid in infants and very young children unless prescribed and dosed by a qualified practitioner. <li> Reasoning: Clinical trial data for Vasavaleha and key constituents are primarily in adults; safety and dosing in small children are not well characterized. <li> Scientific_Study_Title: Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. <li> Scientific_Study_Authors: Szapary PO, et al. <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/12915429/ <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: A randomized controlled trial of standardized guggul extract in adults documented tolerability but also reported hypersensitivity reactions in some participants. The trial’s inclusion criteria excluded children and pregnant/lactating women, and the authors and later reviews note that safety in children remains unproven. Regulatory and review sources therefore recommend avoiding guggul-containing preparations in pediatric populations unless there is clear specialist supervision.</p> </li> </ul> <h4>Diabetes or poor glycemic control (because Vasavaleha often contains honey/jaggery) [In layman terms]</h4> <ul> <li> 🍯 <li> Recommendation: If you have diabetes, discuss with your clinician before using Vasavaleha; if approved, monitor blood glucose closely and use minimal effective amounts or choose a sugar-free formulation. <li> Reasoning: Vasavaleha traditionally uses honey and jaggery as carriers; clinical studies of honey show mixed effects on glycemic control and in some trials higher intakes raised HbA1c in people with type 2 diabetes. <li> Scientific_Study_Title: Effect of Natural Honey on Glycemic Control and Anthropometric Measures of Patients with Type 2 Diabetes: A Randomized Controlled Crossover Trial. <li> Scientific_Study_Authors: Bahrami A., et al. <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/30774837/ <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: In a randomized crossover trial of 53 adults with type 2 diabetes, adding 50 g/day of honey produced a small but measurable increase in HbA1c over eight weeks compared with the control condition. The study concluded that high intake of honey may worsen long-term glycemic markers in some patients with diabetes, supporting a cautious approach to sugar-containing herbal formulations in this population.</p> </li> </ul> <h4>Breastfeeding (limited safety data) [In layman terms]</h4> <ul> <li> 🤱 <li> Recommendation: Prefer avoidance during breastfeeding unless recommended and monitored by a qualified clinician; discuss risk/benefit with your provider. <li> Reasoning: Safety data for many Vasavaleha ingredients in lactation are limited; some constituent actions (hormonal or metabolic) may affect breastfed infants or milk composition. <li> Scientific_Study_Title: Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. <li> Scientific_Study_Authors: Natural Standard Research Collaboration (review) <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/16338199/ <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: Comprehensive reviews of guggul note that safety in pregnancy and lactation is not established and that product labeling and expert reviews commonly advise against use in breastfeeding women. Because clinical trials typically exclude lactating participants, guidance is generally precautionary: avoid until adequate data are available or use only under specialist advice.</p> </li> </ul>
Heading
<h4>Upset stomach / nausea / diarrhea</h4> <ul> <li> 🤢 <li> Side effect summary: Some users report stomach discomfort, increased acidity, loose stools or mild diarrhea-typically with higher doses or in pitta-sensitive people. <li> Recommendation: Reduce dose or take with food; stop if severe or persistent and consult your clinician. <li> Reasoning: Clinical trials of guggul extracts and product reviews report gastrointestinal discomfort as one of the more common, generally mild adverse events. <li> Severity Level: Mild <li> Scientific_Study_Available: Yes <li> Scientific_Study_Title: Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. <li> Scientific_Study_Authors: Szapary PO, et al. <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/12915429/ <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: The randomized trial of standardized guggul extract reported overall tolerability but noted gastrointestinal complaints among treated participants in clinical monitoring. The authors listed GI symptoms and occasional hypersensitivity rashes as the more commonly observed adverse events, typically mild and reversible on discontinuation or dose reduction.</p> </li> </ul> <h4>Skin rash / allergic reaction</h4> <ul> <li> 🧴 <li> Side effect summary: Hypersensitivity skin rashes have been observed with guggul-containing products in clinical trials. <li> Recommendation: Stop the product and seek medical care if a rash, swelling or breathing difficulty occurs. <li> Reasoning: Randomized clinical data recorded dermatologic hypersensitivity in a subset of participants taking guggul extract compared with placebo. <li> Severity Level: Moderate <li> Scientific_Study_Available: Yes <li> Scientific_Study_Title: Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. <li> Scientific_Study_Authors: Szapary PO, et al. <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/12915429/ <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: In this double-blind randomized trial, six participants in guggul groups developed hypersensitivity rashes while none in the placebo group did. The report treats these dermatologic events as notable adverse reactions associated with the extract and recommends monitoring for skin reactions during therapy.</p> </li> </ul> <h4>Interaction-driven altered drug levels (e.g., warfarin, CYP3A substrates)</h4> <ul> <li> ⚠️ <li> Side effect summary: Co-use can change blood levels of concurrent medicines, either reducing or enhancing their effects-leading to under- or over-treatment risks. <li> Recommendation: If you take prescription drugs (especially anticoagulants, hormonal therapies, some statins, or drugs with narrow therapeutic indices), consult your prescriber and arrange monitoring before using Vasavaleha. <li> Reasoning: Mechanistic studies show guggulsterones induce drug-metabolizing enzymes (CYP3A) and case reports document altered warfarin effects after Commiphora exposure. <li> Severity Level: Severe (potentially) - because interactions can be clinically significant. <li> Scientific_Study_Available: Yes <li> Scientific_Study_Title: Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. <li> Scientific_Study_Authors: Brobst DE, Ding X, Creech KL, Goodwin B, Kelley B, Staudinger JL. <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/15075359/ <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: The laboratory research demonstrated that guggulsterones can activate PXR and induce CYP3A enzyme expression in human and rodent hepatocytes. Since many widely prescribed drugs are CYP3A substrates, the authors underscore the potential for clinically meaningful herb-drug interactions and recommend caution when guggul-containing products are used concomitantly with prescription medications.</p> </li> </ul> <h4>Rare severe reaction: rhabdomyolysis and marked muscle enzyme elevation (case report)</h4> <ul> <li> 🚨 <li> Side effect summary: Rare case reports link Commiphora extracts to severe muscle breakdown (rhabdomyolysis) with very high CK levels. <li> Recommendation: If you experience severe muscle pain, weakness, dark urine or extreme fatigue while taking Vasavaleha (especially alongside statins), stop immediately and seek urgent medical care. <li> Reasoning: Although rare, a documented case associated Commiphora mukul to rhabdomyolysis; this signals a need for caution particularly when combined with other lipid-modifying drugs. <li> Severity Level: Severe <li> Scientific_Study_Available: Yes <li> Scientific_Study_Title: Rhabdomyolysis caused by Commiphora mukul, a natural lipid-lowering agent. <li> Scientific_Study_Authors: Bianchi G., et al. <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/15187214/ <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: The published case describes a 55-year-old man who developed life-threatening rhabdomyolysis after two weeks of Commiphora mukul ingestion, with creatine kinase values >100,000 IU/L and marked transaminase elevation; laboratory and clinical recovery followed discontinuation. The authors consider the herb a possible cause and advise surveillance for muscle symptoms when using concentrated Commiphora products.</p> </li> </ul>
Heading
<h4>Drugs primarily metabolized by CYP3A4 (e.g., many statins, some calcium-channel blockers, certain immunosuppressants)</h4> <ul> <li> Interaction_Details: Guggulsterones in Vasavaleha can activate pregnane X receptor and induce CYP3A enzymes, which may increase metabolism and lower blood levels of CYP3A4 substrate drugs, reducing their effectiveness or requiring dose adjustment. <li> Severity: Moderate <li> Recommendation: Consult your prescribing clinician before starting Vasavaleha; consider drug level monitoring or temporary avoidance for critical medications metabolized by CYP3A4. <li> Scientific_Study_Available: Yes <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/15075359/ <li> Scientific_Study_Title: Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. <li> Scientfic_Study_Authors: Brobst DE, Ding X, Creech KL, Goodwin B, Kelley B, Staudinger JL. <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: In vitro and hepatocyte studies demonstrated that guggulsterones bind and activate PXR, elevating CYP3A expression and activity. Because CYP3A is a major clearance pathway for numerous drugs, the authors caution that guggul-derived products could lower co-administered drug concentrations by accelerating metabolism-potentially clinically important for drugs requiring stable therapeutic levels.</p> </li> </ul> <h4>Warfarin and other vitamin-K antagonists / anticoagulants</h4> <ul> <li> Interaction_Details: Botanical resins in the Commiphora genus have been implicated in altering warfarin effect (both reductions and unpredictable changes) via metabolic and pharmacodynamic pathways. <li> Severity: Severe <li> Recommendation: Avoid combining Vasavaleha with warfarin or ensure very close INR monitoring, and discuss alternatives with your clinician. <li> Scientific_Study_Available: Yes (case reports) <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/15814041/ <li> Scientific_Study_Title: Antagonism of the anticoagulant effect of warfarin caused by the use of Commiphora molmol as a herbal medication: a case report. <li> Scientfic_Study_Authors: (authors as indexed on PubMed) <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: The case report documents loss of warfarin anticoagulant effect after the patient began a Commiphora herbal product; anticoagulation control failed until the herb was stopped. The authors conclude the herb likely altered warfarin activity and recommend avoiding herb use with critical anticoagulants without specialist supervision and monitoring.</p> </li> </ul> <h4>Thyroid replacement or antithyroid drugs (levothyroxine, methimazole, propylthiouracil)</h4> <ul> <li> Interaction_Details: Guggul components have been shown in animal and in-vitro studies to modulate thyroid function (increase T3 production/iodine uptake); such effects could change the dose-requirements of thyroid medications. <li> Severity: Moderate <li> Recommendation: If you take thyroid medicines, consult your endocrinologist before using Vasavaleha; monitor thyroid function tests (TSH, free T4/T3) if the herb is started or stopped. <li> Scientific_Study_Available: Yes <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/15798994/ <li> Scientific_Study_Title: Guggulu (Commiphora mukul) potentially ameliorates hypothyroidism in female mice. <li> Scientfic_Study_Authors: Sharma A., et al. <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: Animal experiments reported that Commiphora mukul administration increased T3 and stimulated hepatic deiodinase activity in hypothyroid models, suggesting potential thyromodulatory activity. These preclinical data indicate a plausible interaction with human thyroid replacement therapy and justify careful clinical monitoring when co-administered.</p> </li> </ul> <h4>P-glycoprotein (P-gp) substrate drugs and blood-brain barrier substrates</h4> <ul> <li> Interaction_Details: Experimental data show that Z-guggulsterone can regulate P-glycoprotein ATPase activity and expression, potentially altering distribution and efflux of P-gp substrate drugs (affecting CNS penetration and elimination). <li> Severity: Mild <li> Recommendation: For drugs with narrow therapeutic windows that are P-gp substrates, consult a clinician before concomitant use; monitor for unexpected CNS or systemic effects. <li> Scientific_Study_Available: Yes <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/27000241/ <li> Scientific_Study_Title: Regulation of P-glycoprotein efflux activity by Z-guggulsterone of Commiphora mukul at the blood-brain barrier. <li> Scientfic_Study_Authors: (authors as indexed in PubMed) <li> Scientific_Study_Excerpt: <p>Paraphrase of relevant findings: In rodent systems, Z-guggulsterone increased P-gp ATPase activity and modulated P-gp function, suggesting it can alter efflux transporter activity at the blood-brain barrier. The authors propose that such changes could affect brain exposure to co-administered P-gp substrate drugs and recommend cautious evaluation of possible interactions.</p> </li> </ul>
